Corbus Pharmaceuticals Holdings, Inc. (CRBP) vs Rallybio Corporation (RLYB)

Corbus Pharmaceuticals Holdings, Inc. and Rallybio Corporation are both Biotechnology companies. Corbus Pharmaceuticals Holdings, Inc. and Rallybio Corporation are of similar size ($89.1M and $83.8M). Corbus Pharmaceuticals Holdings, Inc. has negative trailing earnings, so its P/E is not meaningful; Rallybio Corporation trades at 2.0×. Rallybio Corporation grew revenue faster over the last twelve months: 1.18% against −73.7%. Across the 14 metrics below, Rallybio Corporation leads on 10 and Corbus Pharmaceuticals Holdings, Inc. on 4.

Valuation

Metric CRBP RLYB Biotechnology median
P/E n/m 2.02 8.50
P/S 56.97 108.13 9.71
P/B 0.86 0.98 2.13
Price to free cash flow n/m 3.48 20.82
EV/EBITDA 0.07 0.00 0.64
EV/Sales (5.25) (0.08) 9.21
Earnings yield (136.95%) 49.50% (33.15%)
Free cash flow yield (98.82%) 28.76% (25.50%)

Profitability

Metric CRBP RLYB Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (95.58%) 64.86% (56.36%)
Return on assets (80.85%) 61.12% (48.04%)
Return on invested capital 0.00% (1,052.03%) 0.00%

Growth

Metric CRBP RLYB Biotechnology median
Revenue growth (TTM) (73.69%) 1.18% 6.02%
EPS growth (last fiscal year) (60.33%) 85.06% 30.26%
Revenue growth, 5-year CAGR (14.34%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRBP RLYB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.71 27.26 4.72
Net debt to EBITDA 1.90 1.63 0.96

Dividend

Metric CRBP RLYB Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CRBP RLYB Biotechnology median
Market cap 83.75m 89.08m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack